Dr. Pal on Adjuvant Therapy of Renal Cell Carcinoma

Video

In Partnership With:

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy of renal cell carcinoma (RCC).

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy of renal cell carcinoma (RCC).

Today, adjuvant therapy is not a standard of care for localized RCC, though there are studies looking at agents in this space. There are several trials looking at VEGF-directed therapies and it has been demonstrated that patients in the adjuvant setting may not tolerate doses that they would in the metastatic setting.

The only assessment of targeted therapies that has been completed to date is outside the category of VEGF or mTOR inhibition. Girentuximab, which targets CA9, did not have a significant impact on disease-free survival or overall survival.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute